Skip to main navigation Skip to search Skip to main content

A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Subjects with Cystic Fibrosis

Project Details

StatusFinished
Effective start/end date16/08/21 → 21/08/23

Funding

  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$18,011.00